Targets › HLA-DR
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2027.
Open in Phaseline: the race on HLA-DR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Parvus Therapeutics | PVT401 pMHC-peptide nanomedicine: iron oxide nanoparticle core surrounded by dextran linked to mu | HLA-DR | Phase 1 | Inflammatory Bowel Disease (IBD) | Nov 2027 |
Inflammatory Bowel Disease (IBD) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.